Targretin® (bexarotene) is a member of a subclass
of retinoids that selectively activate retinoid X receptors (RXRs). These
retinoid receptors have biologic activity distinct from that of retinoic acid
receptors (RARs). Each soft gelatin capsule for oral administration contains 75
mg of bexarotene.
Targretin ® (bexarotene) capsules are indicated for the treatment of
cutaneous manifestations of cutaneous T-cell lymphoma in patients who are
refractory to at least one prior systemic therapy.
Targretin is also available as a gel.
More information can be reviewed at the following web site (intended for Health
Care Professionals only):